In this article

LLY

NOVO.B-DK

Follow your favorite stocks CREATE FREE ACCOUNT

President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs.

Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350 starting next year, depending on the dosage and insurance coverage a patient has, Trump administration officials said.

Existing GLP-1s, including Eli Lilly's obesity injection Zepbound and Novo Nordisk's competitor Wegovy, carry list prices above $1,000 a month, which has prevented many patients from taking them. Both companies have introduced lower cost options for people paying in cash and purchasing the drugs di

See Full Page